{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:20:39Z","timestamp":1794360039243,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004600","name":"Kyungpook National University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fascin is an actin-binding protein and highly expressed in ovarian cancer cells. It is associated with metastasis of cancer and may be a useful prognostic factor. Anticancer activity of curcumin is related to its effect on several signaling mechanisms. Although there have been many reports regarding the anticancer properties of curcumin, its inhibitory effects on migration and invasion of ovarian cancer cells, particularly in the context of fascin expression, have not been reported. The purpose of this study was to investigate the effect of curcumin on fascin expression in ovarian cancer cells and to propose a possible mechanism for the anticancer activity of curcumin through reduced fascin expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SKOV3, human epithelial ovary cancer cell line, was cultured with curcumin at various dose and duration. The fascin was quantified using cell viability test and Western blot. To determine the effect of curcumin on the upstream pathway of fascin expression, the signal transducer and activator of transcription 3 (STAT3) was analyzed by sandwich-ELISA. Attachment assay, migration assay and invasion assay were analyzed to approve the change of cellular invasiveness of ovary cancer after curcumin. To determine the morphological changes of ovarian cancer cells by curcumin, immunofluorescence was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MTS assays showed that cell viability was different at various concentration of curcumin, and as concentration increased, cell viability tended to decrease. Curcumin appears to suppress fascin expression, even with a minimal concentration and short exposure time. Also, curcumin may suppress fascin expression in ovarian cancer cells through STAT3 downregulation. The attachment assay, migration assay and invasion assay of the ovarian cancer cells exhibited a statistically significant decrease. Immunofluorescence revealed a change of cell shape from a typical form of uninfluenced cells to a more polygonal appearance, with a significant reduction in filopodia formation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Curcumin reduces fascin expression through JAK\/STAT3 pathway inhibition, which interferes with the cellular interactions essential for the metastasis and recurrence of ovarian cancer cells. Higher curcumin concentrations and longer exposure times concomitantly decreased fascin expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-020-01122-2","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T17:45:47Z","timestamp":1605807947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The inhibitory effect of curcumin via fascin suppression through JAK\/STAT3 pathway on metastasis and recurrence of ovary cancer cells"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9770-1580","authenticated-orcid":false,"given":"Mi Ju","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Su","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"1122_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"1122_CR2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519\u201329.","journal-title":"N Engl J Med"},{"issue":"6","key":"1122_CR3","first-page":"1562","volume":"20","author":"PA Vasey","year":"2002","unstructured":"Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, et al. Phase I trial of intraperitoneal injection of the E1B\u201355-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through5 every 3 weeks in patients with recurrent\/refractory epithelial ovarian cancer. J Clin Oncol. 2002;20(6):1562\u20139.","journal-title":"J Clin Oncol"},{"key":"1122_CR4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1388-1981(02)00179-8","volume":"1582","author":"X Fang","year":"2002","unstructured":"Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002;1582:257\u201364.","journal-title":"Biochim Biophys Acta"},{"key":"1122_CR5","doi-asserted-by":"crossref","first-page":"14094","DOI":"10.1073\/pnas.93.24.14094","volume":"93","author":"T Strobel","year":"1996","unstructured":"Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxelinduced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA. 1996;93:14094\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1122_CR6","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/93.18.1375","volume":"93","author":"O Alper","year":"2001","unstructured":"Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst. 2001;93:1375\u201384.","journal-title":"J Natl Cancer Inst"},{"key":"1122_CR7","first-page":"1105","volume":"74","author":"GM Abu-Jawdeh","year":"1996","unstructured":"Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 1996;74:1105\u201315.","journal-title":"Lab Invest"},{"key":"1122_CR8","first-page":"1","volume":"1","author":"A Berkenblit","year":"2001","unstructured":"Berkenblit A, Cannistra SA. Biologic and clinical implications of vascular endothelial growth factor expression in ovarian cancer. Womens Oncol Rev. 2001;1:1\u20138.","journal-title":"Womens Oncol Rev"},{"issue":"Suppl","key":"1122_CR9","first-page":"1S","volume":"20","author":"J Mendelsohn","year":"2002","unstructured":"Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20(Suppl):1S-13S.","journal-title":"J Clin Oncol"},{"key":"1122_CR10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ceb.2011.12.004","volume":"24","author":"JJ Bravo-Cordero","year":"2012","unstructured":"Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012;24:277\u201383.","journal-title":"Curr Opin Cell Biol"},{"key":"1122_CR11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2019.01.020","volume":"153","author":"S McGuire","year":"2019","unstructured":"McGuire S, Kara B, Hart PC, Montag A, Wroblewski K, Fazal S, et al. Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecol Oncol. 2019;153:405\u201315.","journal-title":"Gynecol Oncol"},{"key":"1122_CR12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1741-7015-11-52","volume":"11","author":"VY Tan","year":"2013","unstructured":"Tan VY, Lewis SJ, Adams JC, Martin RM. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 2013;11:52.","journal-title":"BMC Med"},{"issue":"1386\u201396","key":"1122_CR13","first-page":"e1","volume":"146","author":"A Li","year":"2014","unstructured":"Li A, Morton JP, Ma Y, Karim SA, Zhou Y, Faller WJ, et al. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology. 2014;146(1386\u201396):e1-17.","journal-title":"Gastroenterology"},{"key":"1122_CR14","first-page":"371","volume":"33","author":"LC Hanker","year":"2017","unstructured":"Hanker LC, Karn T, Holtrich U, Graeser M, Becker S, Reinhard J, et al. Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer. Anticancer Res. 2017;33:371\u20137.","journal-title":"Anticancer Res"},{"key":"1122_CR15","first-page":"6373","volume":"35","author":"LA Sordillo","year":"2015","unstructured":"Sordillo LA, Sordillo PP, Helson L. Curcumin for the treatment of glioblastoma. Anticancer Res. 2015;35:6373\u20138.","journal-title":"Anticancer Res"},{"key":"1122_CR16","first-page":"363","volume":"23","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363\u201398.","journal-title":"Anticancer Res"},{"key":"1122_CR17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1593\/tlo.09235","volume":"3","author":"W Hartojo","year":"2010","unstructured":"Hartojo W, Silvers AL, Thomas DG, Seder CW, Lin L, Rao H, et al. Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappa B in esophageal adenocarcinoma. Transl Oncol. 2010;3:99\u2013108.","journal-title":"Transl Oncol"},{"key":"1122_CR18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.canlet.2008.03.009","volume":"269","author":"AB Kunnumakkara","year":"2008","unstructured":"Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269:199\u2013225.","journal-title":"Cancer Lett"},{"issue":"Suppl 1","key":"1122_CR19","first-page":"S103","volume":"52","author":"M Lopez-Lazaro","year":"2008","unstructured":"Lopez-Lazaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008;52(Suppl 1):S103-127.","journal-title":"Mol Nutr Food Res"},{"key":"1122_CR20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2174\/1871520614666140521114735","volume":"14","author":"S Zang","year":"2014","unstructured":"Zang S, Liu T, Shi J, Qiao L. Curcumin: a promising agent targeting cancer stem cells. Curr Med Chem Anticancer Agents. 2014;14:787\u201392.","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"1122_CR21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jtcme.2016.08.002","volume":"7","author":"MC Fadus","year":"2017","unstructured":"Fadus MC, Lau C, Bikhchandani J, Lynch HT. Curcumin: an age-old antiinflammatory and anti-neoplastic agent. J Tradit Complement Med. 2017;7:339\u201346.","journal-title":"J Tradit Complement Med"},{"key":"1122_CR22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/etm.2015.2749","volume":"10","author":"D Perrone","year":"2015","unstructured":"Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo L, et al. Biological and therapeutic activities, and anticancer properties of curcumin (review). Exp Ther Med. 2015;10:1615\u201323.","journal-title":"Exp Ther Med"},{"key":"1122_CR23","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.21873\/anticanres.11147","volume":"36","author":"Y Deng","year":"2016","unstructured":"Deng Y, Verron E, Rohanizadeh R. Molecular mechanisms of anti-metastatic activity of curcumin. Anticancer Res. 2016;36:5639\u201347.","journal-title":"Anticancer Res"},{"key":"1122_CR24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.biopha.2018.04.022","volume":"103","author":"Y Ning","year":"2018","unstructured":"Ning Y, Cui Y, Li X, Cao X, Chen A, Xu C, Cao J, Luo X. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8\/STAT3 signaling. Biomed Pharmacother. 2018;103:262\u201371.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1122_CR25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.14791\/btrt.2019.7.e28","volume":"7","author":"KS Park","year":"2019","unstructured":"Park KS, Yoon SY, Park SH, Hwang JH. Anti-migration and anti-invasion effects of curcumin via suppression of fascin expression in glioblastoma cells. Brain Tumor Res Treat. 2019;7(1):16\u201324.","journal-title":"Brain Tumor Res Treat"},{"key":"1122_CR26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/bies.10070","volume":"24","author":"N Kureishy","year":"2002","unstructured":"Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC. Fascins, and their roles in cell structure and function. BioEssays. 2002;24:350\u201361.","journal-title":"BioEssays"},{"key":"1122_CR27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1083\/jcb.200603013","volume":"174","author":"D Vignjevic","year":"2002","unstructured":"Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T, Borisy GG. Role of fascin in filopodial protrusion. J Cell Biol. 2002;174:863\u201375.","journal-title":"J Cell Biol"},{"issue":"11","key":"1122_CR28","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1091\/mbc.e07-02-0157","volume":"18","author":"Y Hashimoto","year":"2007","unstructured":"Hashimoto Y, Parsons M, Adams JC. Dual actin-bundling and protein kinase C-binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. Mol Biol Cell. 2007;18(11):4591\u2013602.","journal-title":"Mol Biol Cell"},{"key":"1122_CR29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12906-019-2685-3","volume":"19","author":"J Koroth","year":"2019","unstructured":"Koroth J, Nirgude S, Tiwari S, Gopalakrishnan V, Mahadeva R, Kumar S, et al. Investigation of anti-cancer and migrastatic properties of novel curcumin derivatives on breast and ovarian cancer cell lines. BMC Complement Altern Med. 2019;19:273.","journal-title":"BMC Complement Altern Med"},{"issue":"6","key":"1122_CR30","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00404-019-05058-3","volume":"299","author":"LD Liu","year":"2019","unstructured":"Liu LD, Pang YX, Zhao XR, Li R, Jin CJ, Xue J, et al. Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT\/mTOR\/p70S6K pathway in human ovarian cancer cells. Arch Gynecol Obstet. 2019;299(6):1627\u201339.","journal-title":"Arch Gynecol Obstet"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01122-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12905-020-01122-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01122-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T17:48:43Z","timestamp":1605808123000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-020-01122-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1122"],"URL":"https:\/\/doi.org\/10.1186\/s12905-020-01122-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-40272\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-40272\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-40272\/v2","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}